BioNotebook: Juno's $134m Series B more than 3 VC deals combined
This article was originally published in Scrip
Juno Therapeutics continues to astound the biotechnology industry and the 2013 startup hasn't even reported any human clinical trial results, but the Seattle, Washington-based company has raised an eye-popping $310m in venture capital financing since its launch in December.
You may also be interested in...
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.